Ulf Jungnelius
Director of the Board and Senior Oncology Advisor
Haematology
Biovica
Sweden
Biography
Ulf Jungnelius is a Director of the Board and Senior Oncology Advisor of the company. Ulf is a board-certified oncologist trained at the Karolinska Institute. In more than 20 years of experience in pharmaceutical drug development, he has been Vice President of Clinical Research and Development, Oncology, at Celgene Inc., and has held similar positions at Pfizer, Eli Lilly, and Takeda Pharmaceuticals in the US. He has had important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta®, and Revlimid®. In addition, his work has been pivotal in several multibillion-dollar acquisitions, such as Celgene’s acquisitions of Abraxis and Pharmion.
Research Interest
Haematology
